- Home
- CTRM vs CRIS Comparison
CTRM vs CRIS Comparison
Compare CTRM & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTRM | CRIS |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 20.6M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CTRM | CRIS |
|---|---|---|
| Price | $2.41 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 49.8K | ★ 280.6K |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.57 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,898,000.00 |
| Revenue This Year | N/A | $27.10 |
| Revenue Next Year | N/A | $67.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 31.50 |
| 52 Week Low | $1.66 | $0.18 |
| 52 Week High | $2.66 | $6.74 |
Technical Indicators
Market Signals| Indicator | CTRM | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 22.67 |
| Support Level | $2.01 | $0.80 |
| Resistance Level | $2.44 | $1.21 |
| Average True Range (ATR) | 0.15 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 43.33 | 4.55 |
Price Performance
Historical ComparisonAbout CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.